Equities Analysts Offer Predictions for SRPT Q1 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at Leerink Partnrs issued their Q1 2026 earnings estimates for Sarepta Therapeutics in a report released on Wednesday, July 16th. Leerink Partnrs analyst J. Schwartz expects that the biotechnology company will earn $0.88 per share for the quarter. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.67 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics’ Q2 2026 earnings at $1.07 EPS.

A number of other equities analysts have also commented on SRPT. UBS Group dropped their price target on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Jefferies Financial Group lowered their price target on shares of Sarepta Therapeutics from $125.00 to $54.00 and set a “buy” rating on the stock in a report on Monday, June 16th. William Blair restated a “market perform” rating on shares of Sarepta Therapeutics in a research note on Thursday. Morgan Stanley restated an “equal weight” rating and issued a $40.00 target price (down previously from $113.00) on shares of Sarepta Therapeutics in a research note on Monday, June 16th. Finally, Needham & Company LLC downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $56.50.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $14.07 on Friday. The firm has a market cap of $1.38 billion, a PE ratio of -5.23 and a beta of 0.45. The firm’s 50 day moving average price is $28.42 and its 200 day moving average price is $68.34. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. Sarepta Therapeutics has a twelve month low of $12.81 and a twelve month high of $150.48.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. Sarepta Therapeutics’s revenue was up 80.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.73 EPS.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Sarepta Therapeutics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock valued at $1,104,701,000 after buying an additional 117,904 shares in the last quarter. Capital International Investors grew its stake in shares of Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after buying an additional 2,437,855 shares in the last quarter. Farallon Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 11.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after buying an additional 285,100 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Sarepta Therapeutics by 27.9% during the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock valued at $168,907,000 after purchasing an additional 577,848 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in Sarepta Therapeutics by 2.1% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company’s stock valued at $127,512,000 after purchasing an additional 41,408 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.